Skip to main content
Throat Cancer Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Hungary, Poland, India - Size and Forecast 2024-2028

Throat Cancer Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Hungary, Poland, India - Size and Forecast 2024-2028

Published: Dec 2023 158 Pages SKU: IRTNTR73577

Market Overview at a Glance

$2.33 B
Market Opportunity
7.51%
CAGR
6.31
YoY growth 2023-2024(%)

Throat Cancer Therapeutics Market Size 2024-2028

The throat cancer therapeutics market size is forecast to increase by USD 2.33 billion at a CAGR of 7.51% between 2023 and 2028.

  • Throat cancer, also known as head and neck cancer, is a significant health concern with increasing incidence rates. This trend is driving the growth of the market. Furthermore, strategic alliances among market companies are enhancing the competitive landscape and contributing to market expansion. 
  • A preference for alternative treatment options, such as immunotherapy and targeted therapy, is also influencing market development. These trends are shaping the future of the market, offering opportunities for stakeholders to capitalize on the growing demand for effective medical technologies. The market's growth is expected to remain robust, providing a favorable business environment for market participants.

What will be the Size of the Throat Cancer Therapeutics Market During the Forecast Period?

Throat Cancer Therapeutics Market Size

 Request Free Sample

  • The market encompasses the development and provision of treatments for various types of throat cancers, including those affecting the voice box, vocal cords, tonsils, oropharynx, and larynx. These malignant growths, often originating from squamous cells, can manifest with symptoms such as chronic sore throat, difficulty swallowing, and hoarseness. Risk factors include use of alcohol and tobacco
  • Throat cancer treatment modalities include radiation therapy, surgery, chemotherapy, targeted drug therapy, and emerging approaches like immunotherapy and precision medicine. Hospitals remain key providers of these services, catering to the needs of patients with conditions like pharyngeal cancer and laryngeal cancer, which can impact the glottis area and cause symptoms such as sore throat and hoarseness.

How is this Throat Cancer Therapeutics Industry segmented and which is the largest segment?

The throat cancer therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

  • Type
    • Pharyngeal cancer
    • Laryngeal cancer
  • Distribution Channel
    • Offline
    • Online
  • Geography
    • North America
      • Canada
      • US
    • Europe
    • Asia
      • India
    • Rest of World (ROW)

By Type Insights

  • The pharyngeal cancer segment is estimated to witness significant growth during the forecast period.

Throat cancer, specifically pharyngeal cancer, is a serious condition characterized by malignant cells developing In the pharynx, a tube extending from the back of the nose to the esophagus. Classified as nasopharynx, oropharynx, and hypopharynx cancer based on the pharynx region, this disease poses a significant health concern due to its potential for rapid spread. Risk factors, such as tobacco usage, alcohol intake, HPV infection, betel juice consumption, and advanced age, contribute to its prevalence. Diagnostic tools like CT scans, PET scans, needle biopsy, MRI scans, thoracoscopy, and mediastinoscopy aid in illness detection. Treatment modalities include surgery, radiation therapy, targeted therapy, chemotherapy using antimetabolites, platinum derivatives, plant derivatives, nitrogen mustards, and antibiotics.

Hospitals, cancer research institutes, multispecialty clinics, and ambulatory surgical centers provide essential services for managing this condition. Key symptoms include persistent sore throat, hoarseness, cough, bad breath, significant weight loss, and constant ear pain. Precision medicine, utilizing genetic information, and oral drugs in capsule or tablet form are emerging trends in pharyngeal cancer therapeutics.

Throat Cancer Therapeutics Market Size

Get a glance at the  Throat Cancer Therapeutics Industry report of share of various segments Request Free Sample

The Pharyngeal cancer segment was valued at USD 2.41 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

  • North America is estimated to contribute 38% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Throat Cancer Therapeutics Market Share by Geography

For more insights on the market share of various regions, Request Free Sample

Throat cancer, including tumors In the voice box, vocal cords, tonsils, oropharynx, larynx, and squamous cells, affects various areas of the throat. In the US, significant numbers of new cases are reported annually, with around 66,000 cases of pharyngeal and laryngeal cancer combined in 2021. Risk factors include chronic sore throat, difficulty swallowing, unhealed mouth sores, raspy voice, enlargement, swollen lymph nodes, and symptoms like persistent cough, hoarseness, persistent bad breath, and significant weight loss. The elderly population is particularly susceptible, with alcohol consumption, HPV infections, and smoking being leading causes. Diagnostic imaging technologies, such as CT scans, PET scans, needle biopsy, MRI scans, thoracoscopy, and mediastinoscopy, aid in illness detection.

Novel technologies and medications, including chemotherapy drugs, antimetabolites, platinum derivatives, plant derivatives, nitrogen mustards, antibiotics, and oral drugs in capsule or tablet form, are used for treatment. Hospitals, cancer research institutes, multispecialty clinics, and ambulatory surgical centers offer various therapies, including surgery, radiation therapy, targeted therapy, chemotherapy, and immunotherapy. The US market for throat cancer therapeutics is substantial due to the advanced healthcare infrastructure and high prevalence of the disease.

Market Dynamics

Our  researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise In the adoption of Throat Cancer Therapeutics Industry?

Increasing incidence of throat cancer is the key driver of the market.

  • Throat cancer, characterized by tumors In the voice box, vocal cords, tonsils, oropharynx, and larynx, affects thousands of individuals each year. Squamous cells, the primary cells affected, can lead to chronic sore throat, difficulty swallowing, unhealed mouth sores, and a raspy voice. Enlargement, swollen lymph nodes, persistent cough, hoarseness, and significant weight loss are other common symptoms. Pharyngeal and laryngeal cancers are the most prevalent types, with risk factors including tobacco usage, alcohol intake, HPV infection, and betel juice consumption. The elderly population and smoking population are disproportionately affected. Diagnostic imaging, such as CT scans, PET scans, needle biopsy, MRI scans, thoracoscopy, and mediastinoscopy, aid in illness detection.
  • Novel technologies, including digital technology-based systems, are increasingly used for precision medicine, utilizing genetic information for oral drugs in capsule or tablet form. Chemotherapy drugs, including antimetabolites, platinum derivatives, plant derivatives, nitrogen mustards, and antibiotics, are common treatments. Surgery and radiation therapy are also used, along with targeted therapy and immunotherapy. Hospitals, cancer research institutes, multispecialty clinics, and ambulatory surgical centers offer these treatments. Symptoms such as persistent cough, hoarseness, sore throat, and difficulty swallowing can lead to appointment systems, routine health services, and telemedicine for early intervention. Alcohol and tobacco usage increase the risk of throat cancer, and health awareness campaigns can help reduce their consumption.
  • Immunotherapy and targeted drug therapy are emerging treatments for throat cancer, offering new hope for patients.

What are the market trends shaping the Throat Cancer Therapeutics Industry?

Growing strategic alliances of the vendors is the upcoming market trend.

  • The market In the US has experienced growth due to an increase in strategic collaborations among companies for the development and commercialization of treatments for various head and neck cancer indications, such as pharyngeal and laryngeal cancer. These partnerships help companies overcome challenges related to research, manufacturing, and commercialization of drugs. For instance, Eli Lilly entered into a licensing agreement with Merck KGaA for the distribution of ERBITUX. Tumors In the voice box, vocal cords, tonsils, oropharynx, and larynx can lead to throat cancer. Symptoms include chronic sore throat, difficulty swallowing, unhealed mouth sores, a raspy voice, enlargement, swollen lymph nodes, and pharyngeal or laryngeal cancer.
  • Risk factors include tobacco usage, alcohol intake, HPV infection, and betel juice consumption. The elderly population and smoking population are particularly susceptible. Diagnostic imaging technologies like CT scans, PET scans, needle biopsy, MRI scans, thoracoscopy, and mediastinoscopy are crucial for illness detection. Novel technologies and medications, including chemotherapy drugs like antimetabolites, platinum derivatives, plant derivatives, nitrogen mustards, and antibiotics, play a significant role in treatment. Precision medicine and genetic information are driving the development of oral drugs in capsule or tablet form. Health awareness, immunotherapy, and routine health services, including appointment systems and telemedicine, are also essential components of the market.
  • Alcohol and tobacco consumption are major contributors to the disease, making health awareness and illness prevention crucial. The market dynamics include the increasing prevalence of throat cancer, advancements in diagnostic technologies, and the development of novel therapies like targeted drug therapy and immunotherapy. The market for throat cancer therapeutics is expected to grow significantly In the coming years.

What challenges does the Throat Cancer Therapeutics Industry face during its growth?

Preference for alternative treatment options is a key challenge affecting the industry growth.

  • Throat cancer, also known as pharyngeal or laryngeal cancer, affects various areas of the throat, including the voice box, vocal cords, tonsils, and oropharynx (the part of the throat at the back of the mouth). Tumors In these regions can cause symptoms such as chronic sore throat, difficulty swallowing, unhealed mouth sores, a raspy voice, enlargement or swollen lymph nodes, and persistent cough or bad breath. Squamous cells, the most common type of cell found In the throat, are the primary cells affected by this cancer. Risk factors for throat cancer include tobacco usage, alcohol intake, and HPV infection.
  • Betel juice is also a known risk factor in certain populations. The elderly population and smoking population are disproportionately affected. Early detection is crucial for effective treatment, and diagnostic imaging technologies such as CT scans, PET scans, needle biopsy, MRI scans, thoracoscopy, and mediastinoscopy are used to identify malignant cells In the glottis area. The market is witnessing significant advancements with the development of novel technologies and medications. Chemotherapy drugs like antimetabolites, platinum derivatives, plant derivatives, nitrogen mustards, and antibiotics are used in combination with targeted drug therapy and immunotherapy to combat the disease. Precision medicine, which uses genetic information to develop oral drugs in capsule or tablet form, is a promising area of research.
  • Patients with throat cancer may experience significant weight loss, constant ear pain, and persistent symptoms. Routine health services, appointment systems, telemedicine, and health awareness campaigns are essential for early detection and effective treatment. The market for throat cancer therapeutics is expected to grow due to the increasing prevalence of throat cancer, the aging population, and the availability of advanced treatment options.

Exclusive Customer Landscape

The throat cancer therapeutics market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the throat cancer therapeutics market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Throat Cancer Therapeutics Market Share by Geography

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, throat cancer therapeutics market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

  • Adlai Nortye Ltd.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol Myers Squibb Co.
  • Celldex Therapeutics Inc.
  • Clinigen Group Plc
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Merck KGaA
  • Moderna Inc
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Throat cancer, also known as head and neck cancer, refers to a group of malignancies that develop In the throat, voice box, tonsils, oropharynx, larynx, and other related structures. These cancers can originate from various types of cells, including squamous cells, which are the most common type. The therapeutic market for throat cancer is driven by several factors. The increasing prevalence of risk factors such as tobacco usage, alcohol intake, HPV infections, and betel juice consumption is a significant contributor. The elderly population is particularly vulnerable due to age-related weakening of the immune system and the higher prevalence of risk factors in this demographic.

The diagnosis and treatment of throat cancer involve various modalities. Diagnostic imaging technologies such as CT scans, PET scans, MRI scans, thoracoscopy, and mediastinoscopy are commonly used for detection. Needle biopsy is another diagnostic technique that involves removing a small sample of tissue for laboratory analysis. Once a diagnosis is confirmed, treatment options include surgery, radiation therapy, targeted therapy, chemotherapy, and immunotherapy. Chemotherapy drugs such as antimetabolites, platinum derivatives, plant derivatives, nitrogen mustards, and antibiotics are used to kill malignant cells. Precision medicine, which utilizes genetic information to tailor treatment to individual patients, is an emerging trend in throat cancer therapeutics.

Oral drugs, available in capsule and tablet form, are also used for the treatment of throat cancer. These medications can be administered at home, providing greater convenience and reducing the need for frequent hospital visits. The therapeutic market for throat cancer is highly competitive, with various hospitals, cancer research institutes, multispecialty clinics, and ambulatory surgical centers offering treatment services. The use of digital technology-based systems for appointment scheduling, telemedicine, and routine health services is becoming increasingly common, streamlining the patient experience and improving access to care. The market for throat cancer therapeutics is expected to grow significantly due to the increasing incidence of throat cancer and the development of novel technologies and medications.

The use of targeted drug therapy, which specifically targets malignant cells while minimizing damage to healthy cells, is a promising area of research. In conclusion, the therapeutic market for throat cancer is driven by several factors, including the increasing prevalence of risk factors, an aging population, and the development of new technologies and medications. The market is highly competitive, with various providers offering a range of treatment options. The use of digital technology to improve access to care and streamline the patient experience is a significant trend in this market.

Market Scope

Report Coverage

Details

Page number

158

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 7.51%

Market growth 2024-2028

USD 2.33 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

6.31

Key countries

US, Canada, Hungary, Poland, and India

Competitive landscape

Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Request Free Sample

What are the Key Data Covered in this Throat Cancer Therapeutics Market Research and Growth Report?

  • CAGR of the Throat Cancer Therapeutics industry during the forecast period
  • Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
  • Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
  • Accurate predictions about upcoming growth and trends and changes in consumer behaviour
  • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market's competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the throat cancer therapeutics market growth of industry companies

We can help! Our analysts can customize this throat cancer therapeutics market research report to meet your requirements.

Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global throat cancer therapeutics market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global throat cancer therapeutics market 2018 - 2022 ($ billion)
    • 4.2 Type Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Type Segment 2018 - 2022 ($ billion)
    • 4.3 Distribution Channel Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Distribution Channel Segment 2018 - 2022 ($ billion)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Type

    • 6.1 Market segments
      • Exhibit 30: Chart on Type - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
    • 6.2 Comparison by Type
      • Exhibit 32: Chart on Comparison by Type
      • Exhibit 33: Data Table on Comparison by Type
    • 6.3 Pharyngeal cancer - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Pharyngeal cancer - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 35: Data Table on Pharyngeal cancer - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 36: Chart on Pharyngeal cancer - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Pharyngeal cancer - Year-over-year growth 2023-2028 (%)
    • 6.4 Laryngeal cancer - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Laryngeal cancer - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 39: Data Table on Laryngeal cancer - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 40: Chart on Laryngeal cancer - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Laryngeal cancer - Year-over-year growth 2023-2028 (%)
    • 6.5 Market opportunity by Type
      • Exhibit 42: Market opportunity by Type ($ billion)
      • Exhibit 43: Data Table on Market opportunity by Type ($ billion)

    7 Market Segmentation by Distribution Channel

    • 7.1 Market segments
      • Exhibit 44: Chart on Distribution Channel - Market share 2023-2028 (%)
      • Exhibit 45: Data Table on Distribution Channel - Market share 2023-2028 (%)
    • 7.2 Comparison by Distribution Channel
      • Exhibit 46: Chart on Comparison by Distribution Channel
      • Exhibit 47: Data Table on Comparison by Distribution Channel
    • 7.3 Offline - Market size and forecast 2023-2028
      • Exhibit 48: Chart on Offline - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 49: Data Table on Offline - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 50: Chart on Offline - Year-over-year growth 2023-2028 (%)
      • Exhibit 51: Data Table on Offline - Year-over-year growth 2023-2028 (%)
    • 7.4 Online - Market size and forecast 2023-2028
      • Exhibit 52: Chart on Online - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 53: Data Table on Online - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 54: Chart on Online - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on Online - Year-over-year growth 2023-2028 (%)
    • 7.5 Market opportunity by Distribution Channel
      • Exhibit 56: Market opportunity by Distribution Channel ($ billion)
      • Exhibit 57: Data Table on Market opportunity by Distribution Channel ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 59: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 60: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 61: Chart on Geographic comparison
      • Exhibit 62: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 63: Chart on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 64: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 65: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 66: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 67: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 68: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 69: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 70: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 71: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 72: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 73: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 74: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 79: Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 80: Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 81: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 India - Market size and forecast 2023-2028
      • Exhibit 83: Chart on India - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 84: Data Table on India - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 85: Chart on India - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on India - Year-over-year growth 2023-2028 (%)
    • 9.9 Hungary - Market size and forecast 2023-2028
      • Exhibit 87: Chart on Hungary - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 88: Data Table on Hungary - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 89: Chart on Hungary - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on Hungary - Year-over-year growth 2023-2028 (%)
    • 9.10 Canada - Market size and forecast 2023-2028
      • Exhibit 91: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 92: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 93: Chart on Canada - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on Canada - Year-over-year growth 2023-2028 (%)
    • 9.11 Poland - Market size and forecast 2023-2028
      • Exhibit 95: Chart on Poland - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 96: Data Table on Poland - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 97: Chart on Poland - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on Poland - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 99: Market opportunity by geography ($ billion)
      • Exhibit 100: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 101: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 103: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 104: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 105: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 106: Matrix on vendor position and classification
            • 12.3 Adlai Nortye Ltd.
              • Exhibit 107: Adlai Nortye Ltd. - Overview
              • Exhibit 108: Adlai Nortye Ltd. - Product / Service
              • Exhibit 109: Adlai Nortye Ltd. - Key offerings
            • 12.4 Amgen Inc.
              • Exhibit 110: Amgen Inc. - Overview
              • Exhibit 111: Amgen Inc. - Product / Service
              • Exhibit 112: Amgen Inc. - Key offerings
            • 12.5 AstraZeneca Plc
              • Exhibit 113: AstraZeneca Plc - Overview
              • Exhibit 114: AstraZeneca Plc - Product / Service
              • Exhibit 115: AstraZeneca Plc - Key news
              • Exhibit 116: AstraZeneca Plc - Key offerings
            • 12.6 Bayer AG
              • Exhibit 117: Bayer AG - Overview
              • Exhibit 118: Bayer AG - Business segments
              • Exhibit 119: Bayer AG - Key news
              • Exhibit 120: Bayer AG - Key offerings
              • Exhibit 121: Bayer AG - Segment focus
            • 12.7 Bristol Myers Squibb Co.
              • Exhibit 122: Bristol Myers Squibb Co. - Overview
              • Exhibit 123: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 124: Bristol Myers Squibb Co. - Key news
              • Exhibit 125: Bristol Myers Squibb Co. - Key offerings
            • 12.8 Celldex Therapeutics Inc.
              • Exhibit 126: Celldex Therapeutics Inc. - Overview
              • Exhibit 127: Celldex Therapeutics Inc. - Product / Service
              • Exhibit 128: Celldex Therapeutics Inc. - Key offerings
            • 12.9 Clinigen Group Plc
              • Exhibit 129: Clinigen Group Plc - Overview
              • Exhibit 130: Clinigen Group Plc - Product / Service
              • Exhibit 131: Clinigen Group Plc - Key offerings
            • 12.10 Eli Lilly and Co.
              • Exhibit 132: Eli Lilly and Co. - Overview
              • Exhibit 133: Eli Lilly and Co. - Product / Service
              • Exhibit 134: Eli Lilly and Co. - Key news
              • Exhibit 135: Eli Lilly and Co. - Key offerings
            • 12.11 F. Hoffmann La Roche Ltd.
              • Exhibit 136: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 137: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 138: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 139: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 140: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.12 Merck KGaA
              • Exhibit 141: Merck KGaA - Overview
              • Exhibit 142: Merck KGaA - Business segments
              • Exhibit 143: Merck KGaA - Key news
              • Exhibit 144: Merck KGaA - Key offerings
              • Exhibit 145: Merck KGaA - Segment focus
            • 12.13 Moderna Inc
              • Exhibit 146: Moderna Inc - Overview
              • Exhibit 147: Moderna Inc - Product / Service
              • Exhibit 148: Moderna Inc - Key offerings
            • 12.14 Novartis AG
              • Exhibit 149: Novartis AG - Overview
              • Exhibit 150: Novartis AG - Business segments
              • Exhibit 151: Novartis AG - Key offerings
              • Exhibit 152: Novartis AG - Segment focus
            • 12.15 Pfizer Inc.
              • Exhibit 153: Pfizer Inc. - Overview
              • Exhibit 154: Pfizer Inc. - Product / Service
              • Exhibit 155: Pfizer Inc. - Key news
              • Exhibit 156: Pfizer Inc. - Key offerings
            • 12.16 Regeneron Pharmaceuticals Inc.
              • Exhibit 157: Regeneron Pharmaceuticals Inc. - Overview
              • Exhibit 158: Regeneron Pharmaceuticals Inc. - Product / Service
              • Exhibit 159: Regeneron Pharmaceuticals Inc. - Key offerings
            • 12.17 Sanofi SA
              • Exhibit 160: Sanofi SA - Overview
              • Exhibit 161: Sanofi SA - Business segments
              • Exhibit 162: Sanofi SA - Key news
              • Exhibit 163: Sanofi SA - Key offerings
              • Exhibit 164: Sanofi SA - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 165: Inclusions checklist
                • Exhibit 166: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 167: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 168: Research methodology
                • Exhibit 169: Validation techniques employed for market sizing
                • Exhibit 170: Information sources
              • 13.5 List of abbreviations
                • Exhibit 171: List of abbreviations

              Research Methodology

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              Interested in this report?

              Get your sample now to see our research methodology and insights!

              Download Now

              Frequently Asked Questions

              Throat Cancer Therapeutics market growth will increase by $ 2.33 bn during 2024-2028 .

              The Throat Cancer Therapeutics market is expected to grow at a CAGR of 7.51% during 2024-2028 .

              Throat Cancer Therapeutics market is segmented by Type( Pharyngeal cancer, Laryngeal cancer) Distribution Channel( Offline, Online, Asia, Rest of World (ROW))

              Adlai Nortye Ltd., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Celldex Therapeutics Inc., Clinigen Group Plc, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Merck KGaA, Moderna Inc, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA are a few of the key vendors in the Throat Cancer Therapeutics market.

              North America will register the highest growth rate of 38% among the other regions. Therefore, the Throat Cancer Therapeutics market in North America is expected to garner significant business opportunities for the vendors during the forecast period.

              US, Canada, Hungary, Poland, India

              • Increasing incidence of throat cancerThe strong prevalence of throat cancer indications and the increasing incidence rate of pharyngeal cancer globally drive the global throat cancer therapeutics market. Despite the increasing advances in the research of therapeutics and the healthcare infrastructure is the driving factor this market.
              • the global throat cancer therapeutics market has witnessed an increase in the number of new cases in recent years. Throat cancer is one of the most common types of cancer in many parts of Europe is the driving factor this market.
              • Asia is the driving factor this market.
              • and North America is the driving factor this market.
              • with pharyngeal cancer being the dominant throat cancer indication is the driving factor this market.
              • followed by laryngeal cancer. Throat cancer cases account for 3% of all new cancer cases in the US every year is the driving factor this market.
              • with the global throat cancer therapeutics market witnessing an increase in its share in recent years. For instance is the driving factor this market.
              • in 2020 is the driving factor this market.
              • about 275 is the driving factor this market.
              • 000 oral cavity cases and 130 is the driving factor this market.
              • 300 pharyngeal cancer cases were reported across the world. According to the NIH is the driving factor this market.
              • laryngeal cancer is the 22nd most common type of cancer in the US and accounts for 0.7% of all new cancer cases every year. In the US is the driving factor this market.
              • in 2021 is the driving factor this market.
              • approximately 54 is the driving factor this market.
              • 000 new total cases of oral cavity and oropharyngeal cancer and 11 is the driving factor this market.
              • 230 deaths from oral cavity or oropharyngeal cancer were reported. Despite the heavy use of therapeutics and the advent of novel drugs such as KEYTRUDA and OPDIVO is the driving factor this market.
              • the mortality rate has increased only due to the lack of diagnosis in the early stages. The high incidence rate and the increasing mortality rate of these indications have resulted in a huge unmet need in the market is the driving factor this market.
              • which is expected to attract pharmaceutical vendors and biotechnology companies to enter the market with novel therapies to cater to the huge unmet need. The market is also witnessing the increasing adoption of therapeutics owing to the recent approvals of novel targeted therapies. This is the driving factor this market.
              • along with the increasing awareness campaigns that aid in the early diagnosis of throat cancer indications is the driving factor this market.
              • is expected to result in the growth of the global throat cancer therapeutics market during the forecast period. is the driving factor this market.

              The Throat Cancer Therapeutics market vendors should focus on grabbing business opportunities from the Pharyngeal cancer segment as it accounted for the largest market share in the base year.